



July 25, 2023

The Honorable James Comer
Chairman
House Committee on Oversight and Accountability
2157 Rayburn House Office Building
Washington DC 20515

The Honorable Jamie Raskin
Ranking Member
House Committee on Oversight and Accountability
2157 Rayburn House Office Building
Washington DC 20515

Dear Chairman Comer and Ranking Member Raskin:

I am writing on behalf of the 45 million Americans – including mothers and caregivers, veterans, athletes, seniors, and more – who rely on the benefits of cannabidiol (CBD) products as a non-pharmaceutical alternative every day. We urge bipartisan action on legislation that authorizes the U.S. Food and Drug Administration (FDA) to regulate CBD as a dietary supplement like it does all other supplements.

Our Coalition supports the Committee's efforts to seek answers for why the FDA has not finished this job that started when Congress passed legislation in the 2018 Farm Bill legalizing hemp-derived CBD products. We strenuously object to the FDA position announced earlier this year to create an unnecessary and burdensome regulatory regime for CBD. Millions of hard-working Americans who rely on CBD do not want or need a pre-emptive, costly, and massive regulatory expansion by the FDA to regulate hemp, which mankind has been cultivating for nearly three thousand years.

With so many families, athletes, seniors, veterans, and others relying on the benefits of CBD, they deserve to know that the CBD products that they consume are independently tested and accurately labeled. Thus, the Coalition urges legislation that would provide FDA the authority it needs to regulate CBD as a dietary supplement under the Federal Food, Drug, and Cosmetic Act. This legislation, which has been needlessly caught up in the larger – and unrelated – discussion about cannabis, has broad bipartisan support, and is non-controversial.

The CBD industry was born from the urgency and necessity of families trying to save the lives of our children, and it has grown into something that is mainstream for American consumers. The tens-of-millions of daily CBD consumers deserve the confidence that comes with independent safety testing, accurate labeling and adverse event reporting required by dietary supplements regulation. What they don't need is more delay and unnecessary pharmaceutical-like bureaucracy at the FDA. It is now time for Congress to step up and help guide this next great American industry.

Sincerely,

A handwritten signature in black ink, appearing to read "Paige Figi".

Paige Figi
Executive Director

cc: Members of the House Committee on Oversight and Accountability
Members of the House Energy and Commerce Committee